98%
921
2 minutes
20
Unlabelled: serovar Kentucky is a frequent cause for clinical infections in human patients. They are isolated and reported with multidrug resistance from the foods of animal origin from various countries. However, studies inferring the colistin resistance are limited. Hence, the current study reports the genetic factors and genomic analysis of the colistin-resistant serovar Kentucky strain COL-R for better understanding of its pathogenic potential and phylogenetic relatedness. The Kentucky strain COL-R was successfully isolated from chicken meat during ongoing surveillance of food of animal origin. Antimicrobial susceptibility testing revealed resistance to cefoxitin, erythromycin, gentamicin, tetracycline, and most disturbingly to ciprofloxacin and colistin (broth microdilution method). Whole-genome sequence of the COL-R strain was subjected to various in silico analysis to identify the virulence factors, antimicrobial resistance genes, pathogenicity islands and sequence type. The . Kentucky COL-R strain belonged to sequence type (ST) 198 with a high probability (0.943) of being a human pathogen. Besides presence of integrated phage in the . Kentucky COL-R genome, 38 genes conferring resistance to various antimicrobials and disinfectants were also identified. Nucleotide Polymorphism analysis indicated triple mutations in A and C genes conferring fluoroquinolone resistance. Phylogenomic analysis with 31 other S. Kentucky genomes revealed discernible clusters with . Kentucky COL-R strain latching onto a cluster of high diversity (geographic location and isolation sources). Taken together, our results document the first occurrence of colistin resistance in a fluoroquinolone resistant . Kentucky COL-R strain isolated from retail chicken and provide crucial information on the genomic features of the strain.
Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-023-03559-2.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133420 | PMC |
http://dx.doi.org/10.1007/s13205-023-03559-2 | DOI Listing |
Microbiol Spectr
August 2025
Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Colistin resistance in carbapenem-resistant (CRKP) poses a significant global health challenge, as colistin remains the last-resort antibiotic for treating multidrug-resistant infections. This study aimed to investigate the prevalence and molecular mechanisms underlying colistin resistance in CRKP (Col-CRKP) isolates in Henan, China, from 2021 to 2024. The minimum inhibitory concentrations of colistin for 134 .
View Article and Find Full Text PDFISME Commun
January 2025
IHPE, Université de Montpellier, CNRS, IFREMER, Université de Perpignan Via Domitia, Place Eugène Bataillon, Montpellier 34090, France.
Colistin is a widespread last resort antibiotic for treatment of multidrug-resistant bacteria. The recent worldwide emergence of colistin resistance (Col-R) conferred by -1 in human pathogens has raised concern, but the putative sources and reservoirs of novel genes in the marine environment remain underexplored. We observed a high prevalence of Col-R, particularly in isolated from European coastal waters by using the same cohorts of oysters as bioaccumulators in three sites across Europe.
View Article and Find Full Text PDFSci Rep
May 2025
Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand.
The growing prevalence of antibiotic resistance in multidrug-resistant Gram-negative bacteria (MDR-GNB), exacerbated by the misuse of antibiotics, presents a critical global health challenge. Colistin, a last-resort antibiotic for severe MDR-GNB infections, has faced diminishing efficacy due to the emergence of colistin-resistant (COL-R) strains. This study evaluates the potential of penfluridol (PF), an antipsychotic drug with notable antibacterial and antibiofilm properties, to restore colistin activity against COL-R GNB in vitro.
View Article and Find Full Text PDFJ Infect Dev Ctries
March 2025
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Cairo, Egypt.
Introduction: Nowadays, treating serious infections caused by multi-drug resistant Gram-negative bacteria is best left to the antiquated medication "colistin.". There have been reports of colistin-resistant (Col-R) and heteroresistant (hR) MDR and XDR-GNB strains worldwide.
View Article and Find Full Text PDFEur J Clin Microbiol Infect Dis
May 2025
Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Purpose: Human health is seriously threatened by carbapenem-resistant Enterobacterales (CRE) due to the lack of effective treatment. The purpose of this study is to examine the efficacy of mefloquine (MEF) together with multiple drugs against 96 clinical CRE isolates including 94 Klebsiella pneumoniae carbapenemase (KPC)-producers or Metallo-β-lactamases (MBLs)-producers and 2 colistin antibiotic resistance enzyme MCR-1-producers.
Methods: Using the broth microdilution method, MICs of MEF in combination with multiple antimicrobial agents, including colistin (COL), imipenem, aztreonam-avibactam (ATM-AVI), ceftazidime-avibactam (CAZ-AVI) for 96 CRE isolates were determined.